Erratum to A comparative study on the activities of six combination regimens againstmultidrug-resistantmycobacterium tuberculosis infection in balb/c mice (Journal of Chemotherapy, (2013), 25, 2, 10.1179/1973947812Y.0000000064);A comparative study on the activities of six combination regimens against multidrugresistant Mycobacterium tuberculosis infection in BALB/c mice

Journal of Chemotherapy

Volumn 25, Issue 2, 2013, Pages 81-86

  Zheng, Meiqin ^a   Jin, Haixia ^a   Fu, Lei ^a   Xu, Jian ^a   Wang, Bin ^a   Zhao, Weijie ^a   Zhu, Hui ^a   Li, Peng ^a   Lu, Yu ^a   Li, Qi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Activity; Combination regimen; Multidrug resistant tuberculosis

Indexed keywords

AMIKACIN; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; LUNG LESION; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SPLEEN WEIGHT;

EID: 84875402005     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1120009X13Z.000000000116     Document Type: Erratum

References (16)

1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis emergency update 2008. [Internet] [cited 2011 June 29]. Available from: http:// www.who.int/tb/challenges/mdr/programmatic_guidelines_for_ mdrtb/en
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis update 2011 [Internet] [cited 2011 June 29]. Available from: http:// www.who.int/tb/challenges/mdr/programmatic_guidelines_for_ mdrtb/en
3. Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49:1447-54.
4. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007;4:e344.
5. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421-6.
6. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med. 2009;180:553-7.
7. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2003;47:3117-22.
8. Klemens SP, DeStefano MS, Cynamon MH. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother. 1993;37:2344-7.
9. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother. 2006;50: 3543-7.
10. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother. 2007;51: 1563-5.
11. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model oftuberculosis. Antimicrob Agents Chemother. 2011;55:5485-92.
12. Lambregts-van Weezenbeek CS, Jansen HM, Nagelkerke NJ, van Klingeren B, Veen J. Nationwide surveillance of drugresistant tuberculosis in The Netherlands: rates, risk factors and treatment outcome. Int J Tuberc Lung Dis. 1998;2:288-95.
13. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis. 1998; 2:877-84.
14. Dhingra VK, Rajpal S, Mittal A, Hanif M. Outcome of multidrug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc. 2008;55:15-21.
15. Cheepsattayakorn A, Cheepsattayakorn R. Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis. Recent Pat Antiinfect Drug Discov. 2012;7:141-56.
16. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of sceond-line antituberculosis drugs [Internet] [cited 2012 Nov 10]. Available from: http:// www.who.int/tb/publications/2008/who_htm_tb_2008_392.pdf